IL214291A - Use of Depriferone to prepare a drug to treat and prevent iron-related eye diseases - Google Patents

Use of Depriferone to prepare a drug to treat and prevent iron-related eye diseases

Info

Publication number
IL214291A
IL214291A IL214291A IL21429111A IL214291A IL 214291 A IL214291 A IL 214291A IL 214291 A IL214291 A IL 214291A IL 21429111 A IL21429111 A IL 21429111A IL 214291 A IL214291 A IL 214291A
Authority
IL
Israel
Prior art keywords
deferiprone
medicament
prevention
iron
preparation
Prior art date
Application number
IL214291A
Other languages
English (en)
Hebrew (he)
Other versions
IL214291A0 (en
Original Assignee
Apotex Technologies Inc
Univ Pennsylvania
Michael Spino
Joshua Lawrence Dunaief
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc, Univ Pennsylvania, Michael Spino, Joshua Lawrence Dunaief filed Critical Apotex Technologies Inc
Publication of IL214291A0 publication Critical patent/IL214291A0/en
Publication of IL214291A publication Critical patent/IL214291A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL214291A 2009-01-26 2011-07-26 Use of Depriferone to prepare a drug to treat and prevent iron-related eye diseases IL214291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (en) 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention of iron-related eye disorders

Publications (2)

Publication Number Publication Date
IL214291A0 IL214291A0 (en) 2011-09-27
IL214291A true IL214291A (en) 2015-03-31

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214291A IL214291A (en) 2009-01-26 2011-07-26 Use of Depriferone to prepare a drug to treat and prevent iron-related eye diseases

Country Status (24)

Country Link
US (1) US20130023569A1 (enExample)
EP (1) EP2389179A4 (enExample)
JP (1) JP5604631B2 (enExample)
KR (1) KR20120078667A (enExample)
CN (1) CN102348456A (enExample)
AP (1) AP2011005843A0 (enExample)
AU (1) AU2009338093B2 (enExample)
BR (1) BRPI0920492A2 (enExample)
CA (1) CA2750599A1 (enExample)
CL (1) CL2011001812A1 (enExample)
CR (1) CR20110456A (enExample)
EA (1) EA201170970A1 (enExample)
IL (1) IL214291A (enExample)
MA (1) MA33090B1 (enExample)
MX (1) MX2011007947A (enExample)
MY (1) MY161269A (enExample)
NI (1) NI201100148A (enExample)
NZ (1) NZ594728A (enExample)
PE (1) PE20120515A1 (enExample)
SG (1) SG173145A1 (enExample)
TN (1) TN2011000366A1 (enExample)
UA (1) UA103366C2 (enExample)
WO (1) WO2010083582A1 (enExample)
ZA (1) ZA201105514B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016205030B2 (en) * 2015-01-09 2021-04-01 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
CN111918646B (zh) 2017-10-25 2022-02-22 奇斯药制品公司 延迟释放去铁酮片剂及其使用方法
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
EP1601367A2 (en) * 2003-02-06 2005-12-07 Bioresponse L.L.C. The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
DK1991225T3 (da) * 2006-02-22 2013-12-16 Apotex Technologies Inc Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern
JP5290147B2 (ja) 2006-04-14 2013-09-18 プラナ バイオテクノロジー リミティッド 加齢黄斑変性症（ａｍｄ）の処置方法
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
EA201170970A1 (ru) 2012-03-30
MA33090B1 (fr) 2012-03-01
NI201100148A (es) 2012-03-06
BRPI0920492A2 (pt) 2019-07-09
UA103366C2 (ru) 2013-10-10
AU2009338093A1 (en) 2011-09-08
JP5604631B2 (ja) 2014-10-08
EP2389179A1 (en) 2011-11-30
AU2009338093B2 (en) 2014-08-28
JP2012515725A (ja) 2012-07-12
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
EP2389179A4 (en) 2012-08-29
SG173145A1 (en) 2011-08-29
MX2011007947A (es) 2011-12-14
NZ594728A (en) 2013-03-28
AP2011005843A0 (en) 2011-08-31
CR20110456A (es) 2012-05-31
PE20120515A1 (es) 2012-05-20
WO2010083582A1 (en) 2010-07-29
CA2750599A1 (en) 2010-07-29
US20130023569A1 (en) 2013-01-24
IL214291A0 (en) 2011-09-27
CL2011001812A1 (es) 2012-02-03
CN102348456A (zh) 2012-02-08
KR20120078667A (ko) 2012-07-10
ZA201105514B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
IL216260A0 (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
AP3155A (en) Methods of administering pirfenidone therapy
SG10201510586PA (en) Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
ZA201402615B (en) Prevention and treatment of ocular conditions
EP2467372A4 (en) TREATMENT OF BDNF ASSOCIATED DISEASES WITH LAQUINIMOD
EP2490635A4 (en) HORN SKIN DENERVATION FOR THE TREATMENT OF EYE DISEASES
IL229786A (en) Use of inhibitors in the preparation of drugs for the treatment of eye diseases
ZA201400616B (en) Methods and devices for drug delivery to ocular tissue using microneedle
IL217768A0 (en) Treatment of crohn's disease with laquinimod
EP2549981A4 (en) INTRAVENOUS CURCUMINE AND DERIVATIVES THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE AND STRESS DISEASES
IL221744A (en) Use of a combination of compounds to prepare a drug to treat Parkinson's disease
PL2701645T3 (pl) Urządzenie do leczenia i/lub zapobiegania chorobom rogówki
SG11201401502TA (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
IL260078B (en) Therapy used to treat Gaucher disease
IL232434B (en) Medicine for medical treatment and/or improvement of sepsis
EP2387407A4 (en) MEDICAMENT FOR THE TREATMENT OF PAIN AND INFLAMMATION
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
IL214291A (en) Use of Depriferone to prepare a drug to treat and prevent iron-related eye diseases
IL216717A (en) Use of benzidamine in the manufacture of a drug for the treatment of p40-dependent diseases
PL2424602T3 (pl) System do dostarczania środka leczniczego do skóry pacjenta
IL197324A0 (en) Synergistic drug combinations for prevention or treatment of glaucoma and ocular hypertension
ZA201304121B (en) Arlysulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
IL231052B (en) Bacteriochlorophyll photosensitizers for the treatment of eye diseases and disorders
HK1148774A (en) Treatment of eye diseases and excessive neovascularization using a combined therapy
HK1174248A (en) Methods of administering pirfenidone therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees